par Saini, Kamal 
;Martins-Branco, Diogo;Tagliamento, Marco;Vidal, Laura;Singh, Navneet;Punie, Kevin;Saini, Monika Lamba;Chico, Isagani;Curigliano, Giuseppe;de Azambuja, Evandro ;Lambertini, Matteo Md Phd M.
Référence Oncology and Therapy, 9, 2, page (255-265)
Publication Publié, 2021-12
;Martins-Branco, Diogo;Tagliamento, Marco;Vidal, Laura;Singh, Navneet;Punie, Kevin;Saini, Monika Lamba;Chico, Isagani;Curigliano, Giuseppe;de Azambuja, Evandro ;Lambertini, Matteo Md Phd M.Référence Oncology and Therapy, 9, 2, page (255-265)
Publication Publié, 2021-12
Article révisé par les pairs
| Résumé : | Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer. |
